AU Patent

AU2020309829B2 — Naltrexone formulation

Assigned to Intas Pharmaceuticals Ltd · Expires 2026-02-05 · 0y expired

What this patent protects

The present invention related to lactose free, stable pharmaceutical composition comprising naltrexone or its pharmaceutically acceptable salt thereof. Further, the present invention provides process for the preparation of the said composition and its use for the treatment of Cro…

USPTO Abstract

The present invention related to lactose free, stable pharmaceutical composition comprising naltrexone or its pharmaceutically acceptable salt thereof. Further, the present invention provides process for the preparation of the said composition and its use for the treatment of Crohn's disease.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020309829B2
Jurisdiction
AU
Classification
Expires
2026-02-05
Drug substance claim
No
Drug product claim
No
Assignee
Intas Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.